Changes in Hong Kong stocks | Hanson Pharmaceuticals (03692) rose nearly 4%, and the median OS of Ruikang rivoltamab reached 18.5 months

The Zhitong Finance App learned that Hanson Pharmaceuticals (03692) rose nearly 4%. As of press release, it had risen 3.73% to HK$33.94, with a turnover of HK$205 million.

According to the news, on September 13, at the first presidential forum of the 2026 World Lung Cancer Conference, Hanson Pharmaceuticals orally reported the mid-phase III ARTEMIS-008 study results of the self-developed B7-H3 targeting ADC, Ruikang rivolutamab (HS-20093) in the form of the latest breakthrough summary. According to the data released this time, Ruikang rivoltamab broke the record for the longest overall survival (OS) in second-line treatment for small cell lung cancer (SCLC). Specifically, the median OS of Recon rivoltamab reached 18.5 months, while the median OS of topotecan was 10.3 months.

Jefferies believes it is confident in Ris-Rez's potential best-in-class (BIC) profile and is expected to further expand to earlier treatments. Motong Daikon pointed out that maintaining Hanson Pharmaceuticals' “gain” rating, the target price is HK$50. It is predicted that its innovative drug sales and licensing revenue will drive the compound annual growth rate of revenue and profit of 12% and 15% respectively from 2020 to 2030. Potential future catalysts include commercial drug sales, key asset data readings, and additional external licensing transactions.